Imke H Bartelink

Summary

Country: The Netherlands

Publications

  1. ncbi Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations
    Imke H Bartelink
    Department of Pharmacy, University Medical Center, Utrecht, The Netherlands
    Clin Pharmacokinet 45:1077-97. 2006
  2. ncbi Predictive performance of a busulfan pharmacokinetic model in children and young adults
    Imke H Bartelink
    Department of Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands
    Ther Drug Monit 34:574-83. 2012
  3. doi Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing
    Rick Admiraal
    Department of Pediatrics, Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Pharmacokinet 54:435-46. 2015
  4. doi Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing
    Imke H Bartelink
    Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Pharmacokinet 51:331-45. 2012
  5. ncbi Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation
    Imke H Bartelink
    Department of Hematology, University Medical Center Utrecht, The Netherlands
    Biol Blood Marrow Transplant 14:88-98. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations
    Imke H Bartelink
    Department of Pharmacy, University Medical Center, Utrecht, The Netherlands
    Clin Pharmacokinet 45:1077-97. 2006
    ..The integration of these guidelines, and combining them with pharmacodynamic effects, should be considered and could form a basis for further study...
  2. ncbi Predictive performance of a busulfan pharmacokinetic model in children and young adults
    Imke H Bartelink
    Department of Clinical Pharmacy, University Medical Center, Utrecht, The Netherlands
    Ther Drug Monit 34:574-83. 2012
    ....
  3. doi Population pharmacokinetic modeling of Thymoglobulin(®) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing
    Rick Admiraal
    Department of Pediatrics, Blood and Marrow Transplantation Program, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Pharmacokinet 54:435-46. 2015
    ..In this study, we describe the population pharmacokinetics of Thymoglobulin(®) as a first step towards an evidence-based dosing regimen of Thymoglobulin(®) in pediatric HCT...
  4. doi Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing
    Imke H Bartelink
    Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands
    Clin Pharmacokinet 51:331-45. 2012
    ..1 to 26 years of age, elucidate patient characteristics that explain the variability in exposure between patients and optimize dosing accordingly...
  5. ncbi Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation
    Imke H Bartelink
    Department of Hematology, University Medical Center Utrecht, The Netherlands
    Biol Blood Marrow Transplant 14:88-98. 2008
    ..TDM was feasible in routine clinical practice. The results show that i.v. Bu using TDM is preferable over oral Bu in children undergoing allogeneic stem cell transplantation, especially in those at high risk for graft failure/relapse...